RS63787B1 - Makrociklična jedinjenja za lečenje bolesti - Google Patents
Makrociklična jedinjenja za lečenje bolestiInfo
- Publication number
- RS63787B1 RS63787B1 RS20221099A RSP20221099A RS63787B1 RS 63787 B1 RS63787 B1 RS 63787B1 RS 20221099 A RS20221099 A RS 20221099A RS P20221099 A RSP20221099 A RS P20221099A RS 63787 B1 RS63787 B1 RS 63787B1
- Authority
- RS
- Serbia
- Prior art keywords
- treating diseases
- macrocyclic compounds
- macrocyclic
- compounds
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607528P | 2017-12-19 | 2017-12-19 | |
| US201862727124P | 2018-09-05 | 2018-09-05 | |
| US201862779283P | 2018-12-13 | 2018-12-13 | |
| PCT/US2018/066158 WO2019126121A1 (en) | 2017-12-19 | 2018-12-18 | Macrocyclic compounds for treating disease |
| EP18893293.3A EP3728271B1 (en) | 2017-12-19 | 2018-12-18 | Macrocyclic compounds for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63787B1 true RS63787B1 (sr) | 2022-12-30 |
Family
ID=66992951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20221099A RS63787B1 (sr) | 2017-12-19 | 2018-12-18 | Makrociklična jedinjenja za lečenje bolesti |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10745416B2 (sr) |
| EP (2) | EP3728271B1 (sr) |
| JP (2) | JP7194188B2 (sr) |
| KR (1) | KR20200101358A (sr) |
| CN (1) | CN111511746B (sr) |
| AU (1) | AU2018392332B2 (sr) |
| BR (1) | BR112020012319A2 (sr) |
| CA (1) | CA3083674A1 (sr) |
| CL (1) | CL2020001632A1 (sr) |
| DK (1) | DK3728271T3 (sr) |
| EC (1) | ECSP20033467A (sr) |
| ES (1) | ES2929467T3 (sr) |
| HR (1) | HRP20221502T1 (sr) |
| HU (1) | HUE060711T2 (sr) |
| IL (1) | IL275265B2 (sr) |
| JO (1) | JOP20200152A1 (sr) |
| LT (1) | LT3728271T (sr) |
| MX (1) | MX2020006490A (sr) |
| PH (1) | PH12020550901A1 (sr) |
| PL (1) | PL3728271T3 (sr) |
| PT (1) | PT3728271T (sr) |
| RS (1) | RS63787B1 (sr) |
| SG (1) | SG11202005590PA (sr) |
| SI (1) | SI3728271T1 (sr) |
| TW (1) | TW201930312A (sr) |
| WO (1) | WO2019126121A1 (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302209B1 (en) | 2015-11-02 | 2024-02-01 | Blueprint Medicines Corp | RET inhibitors |
| MA50398B1 (fr) | 2017-10-18 | 2021-10-29 | Incyte Corp | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma |
| CA3085586A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| WO2019126121A1 (en) | 2017-12-19 | 2019-06-27 | Tp Therapeutics, Inc. | Macrocyclic compounds for treating disease |
| SI3773589T1 (sl) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo |
| WO2020033838A2 (en) | 2018-08-10 | 2020-02-13 | Blueprint Medicines Corporation | Treatment of egfr-mutant cancer |
| CA3117200A1 (en) | 2018-10-22 | 2020-04-30 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| CA3143043A1 (en) | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Polymorphs of a macrocyclic kinase inhibitor |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| BR112022010702A2 (pt) * | 2019-12-03 | 2022-10-04 | Turning Point Therapeutics Inc | Macrociclos para uso no tratamento de doenças |
| CN113754682B (zh) | 2020-06-04 | 2023-01-06 | 赛诺哈勃药业（成都）有限公司 | 具有大环结构的化合物及其用途 |
| WO2023060022A1 (en) * | 2021-10-05 | 2023-04-13 | Turning Point Therapeutics, Inc. | Synthesis of macrocyclic compounds |
| WO2024017380A1 (zh) * | 2022-07-22 | 2024-01-25 | 南京明德新药研发有限公司 | 含三并环的大环类化合物及其应用 |
| WO2024040131A1 (en) * | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ263403A (en) * | 1993-03-25 | 1996-10-28 | Upjohn Co | (oxa)cycloalkyl fused indole and benzofuran amines |
| PL182124B1 (pl) | 1993-12-07 | 2001-11-30 | Lilly Co Eli | Nowe zwiazki oraz srodek farmaceutyczny przeznaczony do leczenia powiklan cukrzycowych lub do leczenia nowotworów PL PL PL PL PL PL PL PL |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| DE60112611T2 (de) | 2000-12-08 | 2006-06-14 | Ortho Mcneil Pharm Inc | Makroheterocyclische verbindungen als kinase inhibitoren |
| EP2334301B1 (en) | 2008-09-08 | 2018-02-14 | Merck Serono SA | Macrocyclics pyrimidines as aurora kinase inhibitors |
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| SI3372605T1 (sl) | 2008-10-22 | 2022-03-31 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-a)pirimidinske spojine kot zaviralci TRK-kinaze |
| CN102271515B (zh) | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
| EP2488521B1 (en) | 2009-10-13 | 2013-12-18 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| EP3521291A1 (en) * | 2010-05-20 | 2019-08-07 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| BR112014003802A2 (pt) | 2011-08-19 | 2017-06-13 | Merck Sharp & Dohme | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento |
| KR20140078710A (ko) | 2011-09-30 | 2014-06-25 | 온코디자인 에스.에이. | 거대고리 flt3 키나제 억제제 |
| AU2013229173B2 (en) | 2012-03-06 | 2017-06-01 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| JP6418950B2 (ja) | 2012-03-09 | 2018-11-07 | レクシコン ファーマシューティカルズ インコーポレイテッド | ピラゾロ［１，５−ａ］ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法 |
| JP6418949B2 (ja) | 2012-03-09 | 2018-11-07 | レクシコン ファーマシューティカルズ インコーポレイテッド | イミダゾ［１，２−ｂ］ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| FI3636649T3 (fi) | 2014-01-24 | 2024-05-02 | Turning Point Therapeutics Inc | Diaryylimakrosyklejä proteiinikinaasien modulaattoreina |
| WO2016014551A1 (en) * | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| BR112018000297A2 (pt) | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| RU2728579C2 (ru) | 2015-07-21 | 2020-07-30 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы и их применение |
| EP3763693A1 (en) * | 2016-03-03 | 2021-01-13 | Shenzhen TargetRx, Inc. | Macrocycle and composition comprising thereof |
| CN106008531B (zh) * | 2016-05-30 | 2019-01-11 | 上海交通大学 | 多环稠合大环内酰胺类化合物的抗胰腺癌用途 |
| EP3490564A4 (en) | 2016-07-28 | 2020-02-26 | Turning Point Therapeutics, Inc. | MACRO CYCLE Kinase Inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| UA126158C2 (uk) | 2017-07-28 | 2022-08-25 | Тьорнінґ Поінт Терапьютикс, Інк. | Макроциклічні сполуки і їх використання |
| MA50398B1 (fr) | 2017-10-18 | 2021-10-29 | Incyte Corp | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma |
| WO2019126121A1 (en) | 2017-12-19 | 2019-06-27 | Tp Therapeutics, Inc. | Macrocyclic compounds for treating disease |
| WO2019126122A1 (en) * | 2017-12-19 | 2019-06-27 | Tp Therapeutics, Inc. | Macrocyclic kinase inhibitors and their use |
| CA3085586A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| GB201721235D0 (en) | 2017-12-19 | 2018-01-31 | Syngenta Participations Ag | Polymorphs |
| WO2019120267A1 (zh) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| CA3099493C (en) | 2018-04-18 | 2023-08-22 | Hitgen Inc. | Macrocyclic kinase inhibitor |
-
2018
- 2018-12-18 WO PCT/US2018/066158 patent/WO2019126121A1/en unknown
- 2018-12-18 AU AU2018392332A patent/AU2018392332B2/en active Active
- 2018-12-18 PL PL18893293.3T patent/PL3728271T3/pl unknown
- 2018-12-18 SI SI201830779T patent/SI3728271T1/sl unknown
- 2018-12-18 JO JOP/2020/0152A patent/JOP20200152A1/ar unknown
- 2018-12-18 EP EP18893293.3A patent/EP3728271B1/en active Active
- 2018-12-18 HR HRP20221502TT patent/HRP20221502T1/hr unknown
- 2018-12-18 LT LTEPPCT/US2018/066158T patent/LT3728271T/lt unknown
- 2018-12-18 MX MX2020006490A patent/MX2020006490A/es unknown
- 2018-12-18 HU HUE18893293A patent/HUE060711T2/hu unknown
- 2018-12-18 SG SG11202005590PA patent/SG11202005590PA/en unknown
- 2018-12-18 KR KR1020207017739A patent/KR20200101358A/ko not_active Application Discontinuation
- 2018-12-18 JP JP2020533594A patent/JP7194188B2/ja active Active
- 2018-12-18 BR BR112020012319-6A patent/BR112020012319A2/pt unknown
- 2018-12-18 EP EP22191652.1A patent/EP4151641A1/en active Pending
- 2018-12-18 RS RS20221099A patent/RS63787B1/sr unknown
- 2018-12-18 CA CA3083674A patent/CA3083674A1/en active Pending
- 2018-12-18 CN CN201880082563.6A patent/CN111511746B/zh active Active
- 2018-12-18 DK DK18893293.3T patent/DK3728271T3/da active
- 2018-12-18 ES ES18893293T patent/ES2929467T3/es active Active
- 2018-12-18 PT PT188932933T patent/PT3728271T/pt unknown
- 2018-12-19 TW TW107145927A patent/TW201930312A/zh unknown
-
2020
- 2020-01-30 US US16/777,717 patent/US10745416B2/en active Active
- 2020-05-05 US US16/866,983 patent/US11286265B2/en active Active
- 2020-06-10 IL IL275265A patent/IL275265B2/en unknown
- 2020-06-15 PH PH12020550901A patent/PH12020550901A1/en unknown
- 2020-06-17 CL CL2020001632A patent/CL2020001632A1/es unknown
- 2020-06-19 EC ECSENADI202033467A patent/ECSP20033467A/es unknown
-
2022
- 2022-02-14 US US17/670,665 patent/US20220306652A1/en active Pending
- 2022-12-09 JP JP2022197141A patent/JP2023027237A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3728271T (lt) | Makrocikliniai junginiai, skirti ligų gydymui | |
| HK1247202A1 (zh) | 用於治療癌症的化合物 | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| IL249229B (en) | Compounds for the treatment of brain cancer | |
| GB201709402D0 (en) | Compounds for treating t-pll | |
| IL251790A0 (en) | Compounds include thiazole for the treatment of culture diseases | |
| ZA201906047B (en) | Compounds for treating tuberculosis | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| GB201716942D0 (en) | Therapeutic compounds | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| EP3383852A4 (en) | COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| EP3261635A4 (en) | Compounds for treating ocular diseases | |
| GB201420348D0 (en) | Compounds for treating neurodegenerative diseases | |
| ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment | |
| GB201715210D0 (en) | Macrocyclic compounds | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| GB201712388D0 (en) | Therapeutic compounds | |
| GB201712390D0 (en) | Therapeutic compounds | |
| GB201712392D0 (en) | Therapeutic compounds | |
| GB201712393D0 (en) | Therapeutic compounds | |
| GB201712394D0 (en) | Therapeutic compounds | |
| GB201712395D0 (en) | Therapeutic compounds | |
| GB201704125D0 (en) | Macrocyclic Compounds | |
| GB201704121D0 (en) | Macrocyclic compounds |